Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robain

Showing results (211-220 of 233) with videos related to

Pageof 24
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 10, 2019
[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review]X Biardeau, R Haddad, C Chesnel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]T Gaillard, M Carton, A Mailliez, et al.
Breast (Edinburgh, Scotland)|February 9, 2021
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME programLuc Cabel, Matthieu Carton, Barbara Pistilli, et al.
BMC Medicine|March 7, 2023
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world databaseCoralie Courtinard, Sophie Gourgou, William Jacot, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 21, 2018
[Cardiovascular adverse effects of antimuscarinics used in the treatment of overactive bladder in the elderly : A review]C Chesnel, A Charlanes, C Hentzen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national studyOlivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, et al.
Pageof 24

Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|January 10, 2019
[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review]X Biardeau, R Haddad, C Chesnel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]T Gaillard, M Carton, A Mailliez, et al.
Breast (Edinburgh, Scotland)|February 9, 2021
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME programLuc Cabel, Matthieu Carton, Barbara Pistilli, et al.
BMC Medicine|March 7, 2023
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world databaseCoralie Courtinard, Sophie Gourgou, William Jacot, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 21, 2018
[Cardiovascular adverse effects of antimuscarinics used in the treatment of overactive bladder in the elderly : A review]C Chesnel, A Charlanes, C Hentzen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national studyOlivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, et al.
Pageof 24